Table 2 Benefits of the I-MPOS approach
From: Patient-controlled encrypted genomic data: an approach to advance clinical genomics
-Simplification of pre-test counselling, informed consent and post-test counselling | |
-Protection of the patient’s privacy and autonomy | |
-Genomic sequencing, even during newborn period, practical, ethical and clinically useful | |
-Increased diagnostic yield; cost-effective approach; decreased time to diagnosis | |
-Overcomes challenges such as shortage of personnel, the management of the huge amount of data generated, incidental findings, VUS, and duty to re-contact. | |
-Incremental integration of genomic technologies into clinical practice. | |
-Standardized approach in medical genomics, even where resources are limited | |
-Promotion of genomic research | |
-Refinement of clinical phenotype: partial matches for known syndromes; biochemical phenotypes | |
-Prevents over-medicalization of genomic data while enabling serving the patient’s concerns | |
-Progressive education of both the health care personnel and the general public regarding personalized/preventive medicine |